Vision Health & Nutrition: Which Nutrients Have Real Research Behind Them
Lutein and zeaxanthin are the two most-cited nutrients in eye-health products, largely because of one landmark government-funded trial. Here's what that trial actually found — including the nuance that tends to get simplified in marketing.
The AREDS2 trial: the actual source of this claim
Most lutein/zeaxanthin claims trace back to a single, large, genuinely rigorous study: the Age-Related Eye Disease Study 2 (AREDS2), a randomized clinical trial funded by the National Eye Institute that enrolled over 4,200 participants already at increased risk of advanced age-related macular degeneration (AMD). It tested adding lutein (10mg) plus zeaxanthin (2mg), omega-3s, or both, to an existing baseline supplement formula.
What it actually found — the nuance matters
In the trial's primary, overall analysis, adding lutein and zeaxanthin did not produce a statistically significant additional reduction in progression to advanced AMD compared to the baseline formula alone. That's an important, often-omitted detail. But a secondary analysis found something more specific: among participants who had low dietary intake of lutein and zeaxanthin to begin with, those who took the supplement were about 25% less likely to progress to advanced AMD than similar low-intake participants who didn't. The trial also found that formulas using lutein/zeaxanthin instead of beta-carotene (the original AREDS formula's ingredient) were associated with an 18% lower rate of progression, which mattered separately because beta-carotene had been linked to increased lung cancer risk in smokers.
What this means in plain terms
This is not a case of "no evidence" — it's a case of evidence that's more specific and conditional than a headline claim suggests. The clearest, most defensible summary of AREDS2: for people already at high risk of AMD progression whose diet is low in these nutrients, supplementation showed a real, measured benefit in a secondary analysis. It is not evidence that lutein/zeaxanthin supplements prevent vision problems in a general, healthy population, and AREDS2 was studying a specific diagnosed eye condition — not general "eye health" as a broad concept.
Sources
"Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration: The AREDS2 Randomized Clinical Trial," JAMA, 2013; "Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 Report No. 3," PubMed; "Long-term Outcomes... AREDS2 Report 28," PubMed, 2022.
Want more research explainers like this?
Get an email when we publish new product reviews and supplement research.